• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
    • Social Work Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
    • Psychiatry News Videos
    • Medication Guide Videos
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • FAQs
  • Med Fact Book App
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Blogs » The Carlat Psychiatry Blog » Pros and Cons of Using TMS for Kids

The Carlat Psychiatry Blog
The Carlat Psychiatry Blog RSS FeedRSS

Pros and Cons of Using TMS for Kids

August 13, 2020
There’s been some promising research for Transcranial Magnetic Stimulation (TMS), but can it be used for treatment-resistant depression in children and adolescents? Here’s a summary of the pros and cons presented in this 2019 article in The Carlat Child Psychiatry Report.

 

Pros:

It seems to work. An open-label trial of TMS for adolescents found a 44% remission rate for kids ages 13-21 years old with Treatment-Resistant Depression. The treatment period was 3 weeks, and even though it’s the largest study we have, it only covered 32 individuals. (MacMaster FP et al, Front Psychiatry 2019;10(article 170);1–6). 

It’s generally safe. A meta-analysis found side effects of TMS treatment were mild and transient. The most frequently reported side effects were headaches (11.5%), scalp discomfort (2.5%), and twitching (1.2%). Again we could use more research, this data came from 48 studies involving 513 participants within the age range of 2.5-17.8 years old. (Krishnan et al, Brain Stimulation 2015;8(1):76–87). 

Won’t affect school work.  Preliminary findings in older adolescents found that TMS doesn’t have negative effects on cognition. In fact, some evidence suggests that TMS may modestly improve verbal memory in older adolescents (Wall CA et al, Front Psychiatry 2013;4(article 165):1–8).

 

Cons:

It’s off-label. TMS is not FDA-approved for depression in children and adolescents. A standardized TMS treatment protocol has not been established yet. 

Unknown long-term effects. Studies are limited and recent. We don’t know if TMS has long-term damaging effects on the developing brain.

Not enough research. It’s challenging to provide reasonable informed consent to patients.

It's relatively expensive. Since each TMS session costs approximately $300-$500, a treatment regimen of 5 sessions per week for the first 4-6 weeks can reach a grand total anywhere from $6,000 to $15,000.

 

Bottom Line: 

Fluoxetine and CBT have the research behind them to be considered first-line treatments for depression in kids. However, when those treatments aren’t working and patients are still suffering, TMS might be a useful option. 

 

Want to learn more? Subscribers can read the full article here.
Carlat Total Access Subscriptions: Get access to every article on the website.

Complete access to every article you search on the website.

Shop for Total Access
Free Psychiatry Updates
The latest unbiased psychiatric information sent to your inbox.
Specify Your Interests
Featured Book
  • HospPsychiatry_Spiral_Binding_Sm.png

    Hospital Psychiatry Fact Book, First Edition (2025) - Spiral Bound

    This comprehensive guide is designed to be a valuable resource for professionals working in...
    READ MORE
Featured Video
  • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
    General Psychiatry

    KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

    Read More
Featured Podcast
  • shutterstock_2622607431.jpg
    General Psychiatry

    Should You Test MTHFR?

    MTHFR is a...
    Listen now
Recommended
  • Join Our Writing Team

    July 18, 2024
    WriteForUs.png
  • Insights About a Rare Transmissible Form of Alzheimer's Disease

    February 9, 2024
    shutterstock_2417738561_PeopleImages.com_Yuri A.png
  • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

    May 24, 2024
    DEA_Checkbox.png
  • Join Our Writing Team

    July 18, 2024
    WriteForUs.png
  • Insights About a Rare Transmissible Form of Alzheimer's Disease

    February 9, 2024
    shutterstock_2417738561_PeopleImages.com_Yuri A.png
  • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

    May 24, 2024
    DEA_Checkbox.png
  • Join Our Writing Team

    July 18, 2024
    WriteForUs.png
  • Insights About a Rare Transmissible Form of Alzheimer's Disease

    February 9, 2024
    shutterstock_2417738561_PeopleImages.com_Yuri A.png
  • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

    May 24, 2024
    DEA_Checkbox.png

About

  • About Us
  • CME Center
  • FAQ
  • Contact Us

Shop Online

  • Newsletters
  • Multimedia Subscriptions
  • Books
  • eBooks
  • ABPN Self-Assessment Courses

Newsletters

  • The Carlat Psychiatry Report
  • The Carlat Child Psychiatry Report
  • The Carlat Addiction Treatment Report
  • The Carlat Hospital Psychiatry Report
  • The Carlat Geriatric Psychiatry Report
  • The Carlat Psychotherapy Report

Contact

carlat@thecarlatreport.com

866-348-9279

PO Box 626, Newburyport MA 01950

Follow Us

Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

© 2025 Carlat Publishing, LLC and Affiliates, All Rights Reserved.